North America Phentermine Hydrochloride Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Capsules, Orally Disintegrating Tablets (ODT), Extended-Release Formulations), By Strength (8 mg, 15 mg, 18.75 mg, 30 mg), By Country (U.S., Canada) and Forecast, 2026-2034

North America Phentermine Hydrochloride Market Trends

Digital prescribing, flexible dosing and formulation diversification

Digital weight-management models are reshaping prescription access through telehealth, smartphone applications and remote monitoring. A 2026 study evaluated 26 commercial digital weight-management interventions and 207 users, finding broad use of self-monitoring and goal-setting functionality. Meanwhile, Lomaira provides an 8 mg formulation that can be administered up to 3 times daily, while conventional phentermine strengths commonly extend to 37.5 mg.

North America Phentermine Hydrochloride Market Drivers

High obesity burden sustains prescription appetite-suppressant utilization

More than 2 in 5 U.S. adults were reported to have obesity, including over 100 million adults, while severe obesity affected more than 22 million people. Adult obesity prevalence increased from 30.5% in 1999–2000 to 41.9% during 2017–March 2020, and obesity-related medical expenditure approached USD 173 billion in 2019 dollars. This large eligible population supports continuing prescription volumes for established oral therapies.

North America Phentermine Hydrochloride Market Restraints

Safety Concerns and Short-Term Treatment Limitations

Safety considerations and the limited duration of approved use can restrain demand for phentermine hydrochloride across North America. U.S. prescribing information indicates that phentermine is intended as a short-term treatment of a few weeks as an adjunct to calorie restriction, exercise, and behavioral modification, limiting its positioning for long-term weight management. The drug is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, pregnancy, nursing, and a history of drug abuse. Prescribers must also consider potential increases in blood pressure, tolerance, and the risk of abuse and dependence. These restrictions narrow the eligible patient population and require careful medical supervision, while the growing availability of longer-term obesity therapies can further reduce the relative attractiveness of short-duration sympathomimetic treatment. These factors restrain the North America Phentermine Hydrochloride Market.

North America Phentermine Hydrochloride Market Opportunities

Telehealth and individualized dosing expand addressable patient access

Prescription digitization creates opportunities across remote consultation, pharmacy fulfillment and longitudinal weight-management services. Digital-intervention research covering 26 commercial platforms and 207 users highlights expanding smartphone-based engagement, while low-dose 8 mg phentermine can be administered as frequently as 3 times daily. Such flexibility complements conventional 15 mg, 30 mg and 37.5 mg formulations.

North America Phentermine Hydrochloride Market Growth is therefore shaped by a large eligible population, established generic infrastructure and digital access, balanced against controlled-substance requirements and newer pharmacological alternatives.

Challenges in North America Phentermine Hydrochloride Market

Abuse Potential and Changing Obesity-Treatment Preferences

Managing the abuse and dependence potential of phentermine while maintaining appropriate access for eligible patients remains a key challenge in North America. U.S. prescribing information classifies phentermine as a Schedule IV controlled substance and notes its chemical and pharmacological relationship to amphetamine-type stimulant drugs, requiring careful prescribing and dispensing practices. The label recommends limiting the quantity dispensed to reduce the possibility of overdosage. In addition, physicians must evaluate cardiovascular risk, medication interactions, tolerance, and patient suitability before treatment. Phentermine's short-term indication also creates a challenge as obesity management increasingly emphasizes sustained treatment strategies. These safety-monitoring, controlled-substance, and evolving treatment-preference requirements can increase compliance burdens and limit broader utilization, creating a continuing challenge for the North America Phentermine Hydrochloride Market.

North America Phentermine Hydrochloride Market Segmentation

The supplied segmentation dataset shows tablets leading dosage forms with 40.30% of 2026 revenue, followed by capsules at 25.15%, ODT at 19.69%, and extended-release formulations at 14.86%. Extended-release formulations record the highest supplied CAGR at 7.65%.

By Dosage Form

Tablets increase from USD 102.88 million in 2025 to USD 110.34 million in 2026 and USD 193.16 million in 2034, registering 7.25% CAGR and approximately 40.30% of 2026 dosage-form revenue.

Extended-release formulations are fastest-growing at 7.65% CAGR, rising from USD 40.70 million in 2026 to USD 73.41 million in 2034. ODT reaches USD 96.80 million at 7.59%, while capsules reach USD 118.30 million at 7.00%.

By Strength

The portfolio covers 8 mg, 15 mg, 18.75 mg, 30 mg and 37.5 mg strengths. The supplied tables do not allocate the USD 273.80 million 2026 dosage-form total or USD 481.67 million 2034 total by strength; therefore, no unsupported strength-level revenue or CAGR is assigned.

The 5-strength architecture supports dose individualization from 8 mg through 37.5 mg. Because no strength-specific CAGR is supplied, identifying a numerical fastest-growing strength would require unsupported assumptions and is excluded.

By Route of Administration

Segmentation includes oral and sublingual routes. The supplied tables quantify USD 273.80 million in 2026 and USD 481.67 million in 2034 by dosage form but provide no 2-route revenue allocation.

Accordingly, neither an oral-versus-sublingual dominance percentage nor route-specific CAGR is fabricated. Commercially documented phentermine products include oral tablets and capsules, including 30 mg and 37.5 mg formulations.

No application-level split of the supplied USD 273.80 million 2026 dosage-form total or 7.37% dosage-form CAGR is available; consequently, application dominance and fastest-growing CAGR are not estimated.

By End User

End users comprise hospitals, ambulatory surgical centers, specialty weight-loss clinics and homecare/telehealth users. The 4-category structure captures institutional and increasingly remote prescription pathways.

No end-user revenue or CAGR allocation is included in the mandatory tables. Therefore, the USD 273.99 million 2026 country total and USD 484.27 million 2034 total are not redistributed using unsupported assumptions.

By Sales Type

Sales are segmented between branded and generic drugs. Generic phentermine commonly spans 15 mg to 37.5 mg, while branded Lomaira provides an 8 mg formulation.

North America Phentermine Hydrochloride Market Country Outlook

U.S.

The U.S. contributes approximately 72.61% of the 2026 country total, increasing from USD 185.25 million in 2025 to USD 198.94 million in 2026 and USD 351.91 million by 2034 at 7.39% CAGR. Its contribution reflects a mature generic supply base and high obesity-treatment utilization.

Canada

Canada accounts for approximately 27.39% in 2026. Revenue increases from USD 69.91 million in 2025 to USD 75.05 million in 2026 and USD 132.36 million by 2034 at 7.35% CAGR, representing an absolute 2026–2034 addition of USD 57.31 million.

North America Phentermine Hydrochloride Market Insights indicate a strongly U.S.-weighted commercial structure, with both countries maintaining CAGRs above 7.3% on their individually supplied forecasts.

Top players in North America Phentermine Hydrochloride Market

• KVK Tech, Inc.
• Teva Pharmaceuticals USA, Inc.
• Elite Laboratories, Inc.
• Lannett Company, Inc.
• Precision Dose, Inc.
• A-S Medication Solutions, LLC
• Bryant Ranch Prepack
• Blenheim Pharmacal, Inc.
• Sun Pharmaceutical Industries Ltd.
• Currax Pharmaceuticals LLC

Top two companies

• KVK Tech, Inc.

Public sources identify KVK as a leading U.S. manufacturer of phentermine and the producer associated with the widely prescribed 37.5 mg tablet and 8 mg Lomaira. More than 7 million phentermine prescriptions have historically been written annually in the U.S. However, a defensible company-specific percentage revenue share is not publicly disclosed in the reviewed sources; assigning one would conflict with the requirement to preserve supplied numerical data.

Recent Developments in North America Phentermine Hydrochloride Market

• 2026: Research published on digital weight-management interventions evaluated 26 commercial solutions and 207 users, reinforcing the growing role of app-based weight-management pathways.
• 2025: Updated DailyMed documentation for Precision Dose-listed 37.5 mg tablets identified Elite Laboratories as manufacturer and packaging configurations of 100 and 1,000 tablets.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year, historical context from 2022–2024, and forecasts through 2034. Mandatory supplied tables are treated as the primary quantitative source: country values total USD 273.99 million in 2026 and USD 484.27 million in 2034, while the dosage-form dataset totals USD 273.80 million and USD 481.67 million respectively. Percentage contributions were calculated directly from these values; no missing strength, route, channel, application, end-user, sales-type, or company-share values were fabricated. Secondary validation used CDC, DailyMed, manufacturer information and published research for epidemiology, product availability, prescribing context and competitive verification.